Chemotherapy – Growth factor support
Treat all patients with growth factor support if dose-dense adjuvant systemic therapy is being prescribed and for other regimens where the risk of febrile neutropenia is higher than 20%.
How this guidance was developed
No evidence-based source recommendation was identified for this topic, which was considered an important aspect of care. This practice point was developed using an expert consensus process.
Chemotherapy – Growth factor support
Treat all patients with growth factor support if dose-dense adjuvant systemic therapy is being prescribed and for other regimens where the risk of febrile neutropenia is higher than 20%.
No evidence-based source recommendation was identified for this topic, which was considered an important aspect of care. This practice point was developed using an expert consensus process.